Hot update initiated MacroGenics, Inc. (MGNX) surge in the Post-market session
MacroGenics, Inc. (NASDAQ: MGNX), shares zipped 13.27% in the post-market to reached $28. A biopharmaceutical corporation devoted to the production and promotion of novel cancer medication monoclonal antibody-based therapeutics has confirmed that the U.S. MARGENZA, in combination with chemotherapy, has been regulated by the FDA for the treatment of adult patients with metastatic HER2-positive breast cancer […]